

Follow the green, high-tech road:

A path to UK growth, net zero and health resilience from innovation in medicines manufacturing

Summary of recommendations

MMIP is making nine key recommendations to government and looks forward to an ongoing partnership to build support for their adoption and implementation:

To drive growth from leadership in environmentally sustainable manufacturing:

- Implement a three-point plan to deliver global leadership in environmentally sustainable medicines manufacturing:
 - Develop an internationally recognised standard for medicines manufacturing Greenhouse Gas emissions
 - Develop a technology and innovation roadmap for environmentally sustainable medicines manufacturing
 - Establish the infrastructure to enable net zero medicines manufacture

To drive growth from leadership in manufacturing innovation:

- £1.1bn over four years to provide sustained, predictable and accessible innovation funding and investment incentives:
 - £200m over four years for collaborative R&D grants
 - £900m over four years for medicines manufacturing capital grant funding to unlock £6bn of industry investment
- Create a five-year digital innovation in medicines manufacturing technology roadmap, including:
 - Establishing a world-class UK Medicines Manufacturing Data Institute
 - Fund next generation oligonucleotide manufacturing capacity

To drive growth by fostering a pro-innovation operating environment:

- Set internationally competitive R&D tax credits, including relief for capital expenditure, and long-term certainty on capital allowances
- Create a medicines manufacturing investment “front door”
- Secure a leading global talent base, including providing additional funding for flexible biomanufacturing skills building on the successful programmes such as the Advanced Therapy Apprenticeship Programme (ATAC) and Skills and Training Network (ATSTN)
- Improve the UK commercial operating environment
- Strengthen health resilience through trade policy and streamlined regulation
- Develop a UK medicines manufacturing investment dashboard



Priorities	Environmentally sustainable manufacturing	Manufacturing innovation	Delivering by 2033
Global leaders in net zero medicines manufacture	Internationally recognised standard for medicines manufacture	£1.1bn over four years for sustained, predictable and accessible innovation funding and investment incentives	<ul style="list-style-type: none"> • 26,500 new jobs in meds manufacturing • Supporting additional 90,100 jobs in the economy • 160 new investments • £3.4bn GVA per annum • Growth in exports • NHS and companies meet net zero targets
Destination country for advanced therapies and manufacturing technology	Technology and innovation roadmap for environmentally sustainable medicines manufacturing	Five-year medicines manufacturing digital innovation technology roadmap	
A resilient UK manufacturing base	Infrastructure to enable Net Zero medicines manufacture		

Life science pro-innovation foundations

- Secure a leading global talent base, including providing additional funding for flexible biomanufacturing skills building on the successful ATAC and ATSTN programmes
- Internationally competitive R&D tax credits, including relief for capital expenditure, and long-term certainty on capital allowances
- A medicines manufacturing investment ‘front door’
- Improve the UK commercial operating environment
- Strengthen health resilience through trade policy and streamlined regulation
- Develop a UK medicines manufacturing investment dashboard